SCHEMBL3374747

SCHEMBL3374747

CS(=O)(=O)Nc1ccc(-c2ccc(F)c(F)c2)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.51
GLO1 Q04760 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
PTGS2 P35354 3/20 0.46
CYP17A1 P05093 1/20 0.44
ADRA2C P18825 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
HAVCR2 Q8TDQ0 2/20 0.43
PGR P06401 2/20 0.42
NR3C1 P04150 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3376954 0.91 KIF11 (0.48) KIF11GAAHPGDMAPK1PTGS2
SCHEMBL3377083 0.91 PTGS2 (0.52) KIF11GAAHPGDMAPK1PTGS2
SCHEMBL3379785 0.87 GAA (0.49) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL3378774 0.85 KIF11 (0.55) KIF11GAAHPGDMAPK1PTGS2
SCHEMBL3378764 0.85 PTGS2 (0.51) KIF11GAAHPGDMAPK1PTGS2
SCHEMBL3378931 0.85 KIF11 (0.67) KIF11GLO1GAAHPGDMAPK1
SCHEMBL3377747 0.84 GLO1 (0.49) KIF11GLO1PTGS2CYP17A1ADRA2C
SCHEMBL3377400 0.83 KIF11 (0.48) KIF11GAAHPGDMAPK1PTGS2
SCHEMBL3374111 0.82 GAA (0.50) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL3378891 0.82 SLC22A12 (0.52) KIF11GAAHPGDMAPK1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KIF11 3561/4885GLO1 2228/4885GAA 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.